schliessen

Filtern

 

Bibliotheken

Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.

PURPOSEWe studied the safety and efficacy of multiple adjuvant apaziquone instillations in patients with high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODSPatients with high risk nonmuscle invasive urothelial carcinoma of the bladder underwent transurethral resection of all bladder t... Full description

Journal Title: The Journal of urology April 2012, Vol.187(4), pp.1195-1199
Main Author: Hendricksen, K
Other Authors: Cornel, E B , de Reijke, T M , Arentsen, H C , Chawla, S , Witjes, J A
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1527-3792 ; DOI: 1527-3792 ; DOI: 10.1016/j.juro.2011.11.101
Link: http://search.proquest.com/docview/929120807/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest929120807
title: Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.
format: Article
creator:
  • Hendricksen, K
  • Cornel, E B
  • de Reijke, T M
  • Arentsen, H C
  • Chawla, S
  • Witjes, J A
subjects:
  • Administration, Intravesical–Administration & Dosage
  • Adult–Administration & Dosage
  • Aged–Drug Therapy
  • Aged, 80 and Over–Pathology
  • Antineoplastic Agents–Surgery
  • Aziridines–Administration & Dosage
  • Carcinoma, Transitional Cell–Drug Therapy
  • Chemotherapy, Adjuvant–Pathology
  • Female–Surgery
  • Humans–Surgery
  • Indolequinones–Surgery
  • Male–Surgery
  • Middle Aged–Surgery
  • Neoplasm Invasiveness–Surgery
  • Prospective Studies–Surgery
  • Risk Factors–Surgery
  • Urinary Bladder Neoplasms–Surgery
  • Abridged
  • Antineoplastic Agents
  • Aziridines
  • Indolequinones
  • Apaziquone
ispartof: The Journal of urology, April 2012, Vol.187(4), pp.1195-1199
description: PURPOSEWe studied the safety and efficacy of multiple adjuvant apaziquone instillations in patients with high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODSPatients with high risk nonmuscle invasive urothelial carcinoma of the bladder underwent transurethral resection of all bladder tumor(s), and received 6 weekly adjuvant intravesical apaziquone instillations of 4 mg in 40 ml. Patients with carcinoma in situ received 3 further maintenance instillations at months 3, 6 and 12. Followup consisted of cystoscopy, urine cytology and observation of adverse events every 3 months for 18 months. RESULTSA total of 53 patients were enrolled in the study. Although all patients were high risk according to the definitions used when the study was initiated, according to most recent guideline criteria, 80% and 20% of these patients would now be considered intermediate and high risk for recurrence, and 50% and 44% would be considered intermediate and high risk for progression, respectively. Intent to treat analysis of 49 patients with papillary tumors showed recurrent tumors in 34.7% and 44.9% at 12 and 18 months, respectively. One patient had progression to T2 or greater urothelial carcinoma after 9 months. There were 4 patients with carcinoma in situ who had complete responses at 3 months but discontinued treatment due to cystitis, recurrent papillary disease, urinary incontinence and dysuria. Most other side effects were mild (grade 1 to 2). CONCLUSIONSAdjuvant intravesical instillations of apaziquone are generally well tolerated. The recurrence rates of 34.7% after 12 months and 44.9% after 18 months in these patients can be considered encouraging, and warrant further study.
language: eng
source:
identifier: E-ISSN: 1527-3792 ; DOI: 1527-3792 ; DOI: 10.1016/j.juro.2011.11.101
fulltext: fulltext
issn:
  • 15273792
  • 1527-3792
url: Link


@attributes
ID552390719
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid929120807
sourceidproquest
recordidTN_proquest929120807
sourcesystemOther
pqid929120807
galeid283356022
display
typearticle
titlePhase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.
creatorHendricksen, K ; Cornel, E B ; de Reijke, T M ; Arentsen, H C ; Chawla, S ; Witjes, J A
contributorHendricksen, K (correspondence author) ; Hendricksen, K (record owner)
ispartofThe Journal of urology, April 2012, Vol.187(4), pp.1195-1199
identifier
subjectAdministration, Intravesical–Administration & Dosage ; Adult–Administration & Dosage ; Aged–Drug Therapy ; Aged, 80 and Over–Pathology ; Antineoplastic Agents–Surgery ; Aziridines–Administration & Dosage ; Carcinoma, Transitional Cell–Drug Therapy ; Chemotherapy, Adjuvant–Pathology ; Female–Surgery ; Humans–Surgery ; Indolequinones–Surgery ; Male–Surgery ; Middle Aged–Surgery ; Neoplasm Invasiveness–Surgery ; Prospective Studies–Surgery ; Risk Factors–Surgery ; Urinary Bladder Neoplasms–Surgery ; Abridged ; Antineoplastic Agents ; Aziridines ; Indolequinones ; Apaziquone
descriptionPURPOSEWe studied the safety and efficacy of multiple adjuvant apaziquone instillations in patients with high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODSPatients with high risk nonmuscle invasive urothelial carcinoma of the bladder underwent transurethral resection of all bladder tumor(s), and received 6 weekly adjuvant intravesical apaziquone instillations of 4 mg in 40 ml. Patients with carcinoma in situ received 3 further maintenance instillations at months 3, 6 and 12. Followup consisted of cystoscopy, urine cytology and observation of adverse events every 3 months for 18 months. RESULTSA total of 53 patients were enrolled in the study. Although all patients were high risk according to the definitions used when the study was initiated, according to most recent guideline criteria, 80% and 20% of these patients would now be considered intermediate and high risk for recurrence, and 50% and 44% would be considered intermediate and high risk for progression, respectively. Intent to treat analysis of 49 patients with papillary tumors showed recurrent tumors in 34.7% and 44.9% at 12 and 18 months, respectively. One patient had progression to T2 or greater urothelial carcinoma after 9 months. There were 4 patients with carcinoma in situ who had complete responses at 3 months but discontinued treatment due to cystitis, recurrent papillary disease, urinary incontinence and dysuria. Most other side effects were mild (grade 1 to 2). CONCLUSIONSAdjuvant intravesical instillations of apaziquone are generally well tolerated. The recurrence rates of 34.7% after 12 months and 44.9% after 18 months in these patients can be considered encouraging, and warrant further study.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/929120807/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Hendricksen, K
1Cornel, E B
2de Reijke, T M
3Arentsen, H C
4Chawla, S
5Witjes, J A
titlePhase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.
descriptionPURPOSEWe studied the safety and efficacy of multiple adjuvant apaziquone instillations in patients with high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODSPatients with high risk nonmuscle invasive urothelial carcinoma of the bladder underwent transurethral resection of all bladder tumor(s), and received 6 weekly adjuvant intravesical apaziquone instillations of 4 mg in 40 ml. Patients with carcinoma in situ received 3 further maintenance instillations at months 3, 6 and 12. Followup consisted of cystoscopy, urine cytology and observation of adverse events every 3 months for 18 months. RESULTSA total of 53 patients were enrolled in the study. Although all patients were high risk according to the definitions used when the study was initiated, according to most recent guideline criteria, 80% and 20% of these patients would now be considered intermediate and high risk for recurrence, and 50% and 44% would be considered intermediate and high risk for progression, respectively. Intent to treat analysis of 49 patients with papillary tumors showed recurrent tumors in 34.7% and 44.9% at 12 and 18 months, respectively. One patient had progression to T2 or greater urothelial carcinoma after 9 months. There were 4 patients with carcinoma in situ who had complete responses at 3 months but discontinued treatment due to cystitis, recurrent papillary disease, urinary incontinence and dysuria. Most other side effects were mild (grade 1 to 2). CONCLUSIONSAdjuvant intravesical instillations of apaziquone are generally well tolerated. The recurrence rates of 34.7% after 12 months and 44.9% after 18 months in these patients can be considered encouraging, and warrant further study.
subject
0Administration, Intravesical–Administration & Dosage
1Adult–Administration & Dosage
2Aged–Drug Therapy
3Aged, 80 and Over–Pathology
4Antineoplastic Agents–Surgery
5Aziridines–Administration & Dosage
6Carcinoma, Transitional Cell–Drug Therapy
7Chemotherapy, Adjuvant–Pathology
8Female–Surgery
9Humans–Surgery
10Indolequinones–Surgery
11Male–Surgery
12Middle Aged–Surgery
13Neoplasm Invasiveness–Surgery
14Prospective Studies–Surgery
15Risk Factors–Surgery
16Urinary Bladder Neoplasms–Surgery
17Abridged
18Antineoplastic Agents
19Aziridines
20Indolequinones
21Apaziquone
general
0English
11527-3792
210.1016/j.juro.2011.11.101
3MEDLINE (ProQuest)
4ProQuest Biological Science Collection
5ProQuest Natural Science Collection
6ProQuest SciTech Collection
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest929120807
issn
015273792
11527-3792
rsrctypearticle
creationdate2012
addtitleThe Journal of urology
searchscope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
scope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
lsr43
01007527false
11007944false
210000004false
310000038false
410000050false
510000120false
610000159false
710000238false
810000253false
910000260false
1010000270false
1110000271false
1210000302false
contributorHendricksen, K
startdate20120401
enddate20120401
citationpf 1195 pt 1199 vol 187 issue 4
lsr30VSR-Enriched:[galeid, pqid, issn, date]
sort
titlePhase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.
authorHendricksen, K ; Cornel, E B ; de Reijke, T M ; Arentsen, H C ; Chawla, S ; Witjes, J A
creationdate20120401
lso0120120401
facets
frbrgroupid4550041721343824706
frbrtype5
newrecords20181218
languageeng
creationdate2012
topic
0Administration, Intravesical–Administration & Dosage
1Adult–Administration & Dosage
2Aged–Drug Therapy
3Aged, 80 and Over–Pathology
4Antineoplastic Agents–Surgery
5Aziridines–Administration & Dosage
6Carcinoma, Transitional Cell–Drug Therapy
7Chemotherapy, Adjuvant–Pathology
8Female–Surgery
9Humans–Surgery
10Indolequinones–Surgery
11Male–Surgery
12Middle Aged–Surgery
13Neoplasm Invasiveness–Surgery
14Prospective Studies–Surgery
15Risk Factors–Surgery
16Urinary Bladder Neoplasms–Surgery
17Abridged
18Antineoplastic Agents
19Aziridines
20Indolequinones
21Apaziquone
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Hendricksen, K
1Cornel, E B
2de Reijke, T M
3Arentsen, H C
4Chawla, S
5Witjes, J A
jtitleJournal of urology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Hendricksen
1Cornel
2de Reijke
3Arentsen
4Chawla
5Witjes
aufirst
0K
1E B
2T M
3H C
4S
5J A
au
0Hendricksen, K
1Cornel, E B
2de Reijke, T M
3Arentsen, H C
4Chawla, S
5Witjes, J A
addauHendricksen, K
atitlePhase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.
jtitleThe Journal of urology
risdate20120401
volume187
issue4
spage1195
epage1199
pages1195-1199
eissn1527-3792
formatjournal
genrearticle
ristypeJOUR
abstractPURPOSEWe studied the safety and efficacy of multiple adjuvant apaziquone instillations in patients with high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODSPatients with high risk nonmuscle invasive urothelial carcinoma of the bladder underwent transurethral resection of all bladder tumor(s), and received 6 weekly adjuvant intravesical apaziquone instillations of 4 mg in 40 ml. Patients with carcinoma in situ received 3 further maintenance instillations at months 3, 6 and 12. Followup consisted of cystoscopy, urine cytology and observation of adverse events every 3 months for 18 months. RESULTSA total of 53 patients were enrolled in the study. Although all patients were high risk according to the definitions used when the study was initiated, according to most recent guideline criteria, 80% and 20% of these patients would now be considered intermediate and high risk for recurrence, and 50% and 44% would be considered intermediate and high risk for progression, respectively. Intent to treat analysis of 49 patients with papillary tumors showed recurrent tumors in 34.7% and 44.9% at 12 and 18 months, respectively. One patient had progression to T2 or greater urothelial carcinoma after 9 months. There were 4 patients with carcinoma in situ who had complete responses at 3 months but discontinued treatment due to cystitis, recurrent papillary disease, urinary incontinence and dysuria. Most other side effects were mild (grade 1 to 2). CONCLUSIONSAdjuvant intravesical instillations of apaziquone are generally well tolerated. The recurrence rates of 34.7% after 12 months and 44.9% after 18 months in these patients can be considered encouraging, and warrant further study.
doi10.1016/j.juro.2011.11.101
urlhttp://search.proquest.com/docview/929120807/
issn00225347
date2012-04